3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Kemurnian> 99,0% Pabrik Penengah Lenalidomide
Ruifu Chemical minangka produsen utama 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) kanthi kualitas tinggi, perantara Pomalidomide (CAS: 19171-19-8).Ruifu Chemical bisa nyedhiyakake pangiriman ing saindenging jagad, rega sing kompetitif, layanan sing apik, jumlah cilik lan akeh sing kasedhiya.Tuku 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Jeneng Kimia | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| sinonim | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Nomer CAS | 24666-56-6 |
| CAS sing gegandhengan | 2686-86-4;25181-50-4 |
| Status Simpenan | Ing Simpenan, Skala Produksi Nganti Ton |
| Formula Molekul | C5H9ClN2O2 |
| Bobot Molekul | 164.59 |
| Titik Lebur | 120 ℃ |
| COA & MSDS | kasedhiya |
| asale | Shanghai, China |
| Merk | Kimia Ruifu |
| Item | Spesifikasi |
| Penampilan | Bubuk Kristal Putih Putih |
| Kemurnian / Metode Analisis | > 99,0% (HPLC) |
| Kelembapan (KF) | <0,50% |
| Mundhut ing Pangatusan | <0,50% |
| Sisa ing Ignition | <0,20% |
| Total Impurities | <1.00% |
| Spektrum Infra Merah | Conforms kanggo Struktur |
| Test Standar | Standar Perusahaan |
| Panggunaan | Penengah Lenalidomide (CAS: 191732-72-6) |
Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan
Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan
3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) minangka perantara kanggo nyiapake Lenalidomide (CAS: 191732-72-6).Lenalidomide minangka jinis obat antitumor sing dikembangake dening perusahaan farmasi biologi Amerika.Nduwe akeh fungsi kayata anti-tumor, regulasi kekebalan lan anti-angiogenesis.Bisa nyandhet sekresi sitokin inflamasi, lan nambah sekresi sitokin anti-inflamasi mononuklear getih perifer.Bisa nyandhet wutah saka macem-macem sel myeloma patients lan sel MM1S.Loro studi klinis sing dikontrol plasebo kanthi acak kaping pindho multisenter ngevaluasi efek safety lan curative saka lenalidomide sing digunakake kanggo macem-macem myeloma.Hasil riset klinis anyar nuduhake yen lenalidomide ora mung nduweni efek curative ing nambani MDS lan MM, nanging uga ing nambani myeloma, leukemia, metastatik karsinoma sel ginjel, tumor ngalangi, amyloidosis generalized idiopathic lan penyakit fibrosis sumsum balung sistemik karo sumsum unripe.Ing Desember 2005, US Food and Drug Administration (FDA) nyetujoni lenalidomide kanggo digunakake ing perawatan sindrom myelodysplastic (MDS).
